Patients on both DPP4 inhibitors and metformin, which has also been associated with tumor suppression, had even more pronounced of a survival advantage, suggesting a synergistic effect (HR: 0.83; 95% CI: 0.77-0.90; p < 0.0001) [4]. This evidence concerns the gene DPP4 and neoplasm.